Carl E. Allen

Target and Agent Prioritization for the Children’s Oncology Group—National Cancer Institute Pediatric MATCH Trial

M. Lim, P. Adamson, T. Laetsch, 2017, Journal of the National Cancer Institute.

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.

D. Muzny, D. Wheeler, L. Treviño, 2014, Blood.

Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis.

D. Wheeler, D. Parsons, N. Kakkar, 2016, Blood.

Cell-Specific Gene Expression in Langerhans Cell Histiocytosis Lesions Reveals a Distinct Profile Compared with Epidermal Langerhans Cells

M. Merad, T. Man, M. Hicks, 2010, The Journal of Immunology.

A genome-wide association study of LCH identifies a variant in SMAD6 associated with susceptibility.

J. Belmont, M. Merad, M. Scheurer, 2017, Blood.